{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:14:23Z","timestamp":1773144863621,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T00:00:00Z","timestamp":1319673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1038\/bjc.2011.389","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T22:50:07Z","timestamp":1319755807000},"page":"1635-1639","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies"],"prefix":"10.1038","volume":"105","author":[{"given":"V","family":"Gr\u00fcnwald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Weikert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,27]]},"reference":[{"issue":"Suppl 15","key":"BFbjc2011389_CR1","first-page":"2010","volume":"28","author":"E Angevin","year":"2010","unstructured":"Angevin E, Lin C, Pande AU, Lopez JA, Gschwend J, Harzstark AL, Shi M, Anak O, Escudier B (2010) A phase I\/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results. J Clin Oncol 28 (Suppl 15): 2010\u20133057","journal-title":"J Clin Oncol"},{"issue":"6","key":"BFbjc2011389_CR2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.eururo.2010.09.008","volume":"58","author":"G Di Lorenzo","year":"2010","unstructured":"Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D\u2019Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V (2010) Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 58 (6): 906\u2013911","journal-title":"Eur Urol"},{"key":"BFbjc2011389_CR3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103\u20132111","journal-title":"Lancet"},{"key":"BFbjc2011389_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000328575","volume":"34","author":"V Gr\u00fcnwald","year":"2011","unstructured":"Gr\u00fcnwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, Reuter C, Ganser A, Johannsen M (2011) Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie 34: 1\u20131","journal-title":"Onkologie"},{"issue":"12","key":"BFbjc2011389_CR5","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/cncr.25750","volume":"117","author":"DY Heng","year":"2011","unstructured":"Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, Rini BI, Choueiri TK (2011) Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 117 (12): 2637\u20132642","journal-title":"Cancer"},{"key":"BFbjc2011389_CR6","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794\u20135799","journal-title":"J Clin Oncol"},{"key":"BFbjc2011389_CR7","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Global ARCC Trial temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271\u20132281","journal-title":"N Engl J Med"},{"key":"BFbjc2011389_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289\u2013296","journal-title":"J Clin Oncol"},{"key":"BFbjc2011389_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449\u2013456","journal-title":"Lancet"},{"key":"BFbjc2011389_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115\u2013124","journal-title":"N Engl J Med"},{"key":"BFbjc2011389_CR11","unstructured":"Schwandt A, Wood L, Bukowski RM, Elson P, Garcia JA, Gilligan T, Dreicer R, Mekhail T, Rini BI (2009) Temsirolimus in metastatic renal cell carcinoma: safety and efficacy in patients previously treated with VEGF-targeted therapy. ASCO Genitourinary Cancers Symposium (abstract no. 293)"},{"key":"BFbjc2011389_CR12","doi-asserted-by":"crossref","unstructured":"Seidel C, Fenner M, Reuter C, Ganser A, Gr\u00fcnwald V (2011) Progression free survival (PFS) of first line VEGF targeted therapy is a prognostic parameter for overall survival (OS) in patients with metastatic renal carcinoma (mRCC). J Clin Oncol 29 (Suppl): (Abstract No. 4591)","DOI":"10.1200\/jco.2011.29.15_suppl.4591"},{"key":"BFbjc2011389_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarb\u00e1 JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061\u20131068","journal-title":"J Clin Oncol"},{"issue":"3","key":"BFbjc2011389_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3): 205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2011389_CR15","doi-asserted-by":"crossref","unstructured":"Weikert S, Kempkensteffen C, Gruenwald V, Zimmermann K, Fl\u00f6rcken A, Westermann J, Miller K, Johannsen M, Keilholz U (2010) Sequential use of temsirolimus (TEM) in patients with metastatic renal cell carcinoma (mRCC): safety and efficacy following failure of receptor tyrosine kinase inhibitor (TKI) treatment. ASCO Genitourinary Cancers Symposium (Abstract No. 352)","DOI":"10.1016\/S1569-9056(10)60101-7"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2011389.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011389","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011389.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:03:45Z","timestamp":1684415025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2011389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,27]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["BFbjc2011389"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2011.389","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,27]]}}}